Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Maintains Overweight on Comerica, Lowers Price Target to $97

JP Morgan analyst Steven Alexopoulos maintains Comerica (NYSE:CMA) with a Overweight and lowers the price target from $108 to $97.
byBenzinga Newsdesk
July 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

JP Morgan analyst Steven Alexopoulos maintains Comerica (NYSE:CMA) with a Overweight and lowers the price target from $108 to $97.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

FDA Refuses Neurology-Focused Clene’s Accelerated Approval For Amyotrophic Lateral Sclerosis Treatment, Shares Fall

By Vandana Singh
December 21, 2:02 PM
Clene Inc (NASDAQ: CLNN) provided an amyotrophic lateral sclerosis (ALS) regulatory update from its recent meeting with the FDA to discuss CNM-Au8 for ALS, presenting initial clinical and Neurofilament Light Chain (NfL) biomarker results from the completed 

CLNN